1 / 7

Tuncay Teksöz

Panel: Entrepreneurial Ecosystem Models around the World. Turkey’s Industrial Transformation Target & IP Pharma-Perspective. Tuncay Teksöz. Pfizer Turkey Health & Value and Public Affairs Director. Turkey Needs an Industrial Transformation t o Restore High Economic Growth.

felixe
Télécharger la présentation

Tuncay Teksöz

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Panel:Entrepreneurial Ecosystem Models around the World Turkey’s Industrial Transformation Target & IP Pharma-Perspective Tuncay Teksöz Pfizer Turkey Health & Value and Public Affairs Director

  2. Turkey Needs an Industrial Transformation to Restore High Economic Growth Moderated growth since 2012: Below the level to converge with developed economies Turkey is the world’s 17th largest economy • Lack of qualification in manufacturing • Problemsin creating high added value • Insufficientcompetitive power in exports Middle Income Trap GDP/cap,1000$ Mainassets: Young, dynamic population, a large domestic market, and a strategic location Industrial Transformation to improve international competitiveness

  3. Industrial Transformation towards High-Tech Addressed in National Strategies Focusing Healthcare Industries is NOT a Coincidence A Platform Industry - Biotechnology Increasedcompetitiveness has a positive impact to other industries’s potential to make Turkey’s export basket richer. High Resource Allocation for R&D $135B worldwide spending for pharmaceutical innovation; TR gets only 0,038%* Bloomberg data, Capital IQ data, Strategy& analysis * TEPAV hesaplamaları CHALLENGE: TARGETS: • Increasing share of local production from 50% to 60% • by value terms • Discovery of at least one original product and/or repositioningtwo molecules in different indications • 25% increase in clinical trials annually • Can it be realized? • Are they right KPIs heading to international competitiveness? • Do we have a suitable ecosystem?

  4. Panoramic View of Innovation Ecosystem for Biotechnology IP Protection Patent Strength Perceived IP Protection Partnerships for Access to Global Markets Enterprise Support Business Friendly Environment • Biotech VC, 2007($mm) • VC availability • Capital availability Intensity Pricing & Reimbursement Policies Market Access Conditions • Biotech patents/ total patents filled wPCT • Value added of konwledge and tech intensive industries • Business expenditures on biotech R&D Foundation • Business expenditures on R&D (%GDP) • Gross domestic expenditure on R&D (%GDP) • Infrastructure quality • Entrepreneurship and opportunity • Public – Private – Univ Partnership Platforms • Access to Global R&D Networks Education & Workforce • Post secondary science graduates/cap • PhD graduates in lifesciences per million popl • R&D personnel per 1000 employement • Talent retention • Brain gain (share of global students outside country) • Political stability and absence of terror • Government effectiveness • Regulatory quality • Rule of law Scientific American Worldview Scorecard, 2016: Innovationpotential in biotechnology around the world Policy & Stability

  5. Innovation Potential in Biotechnology vs IP Protection Where does Turkey Stand? Countries Pharma-Industry Showcase Upper Middle Income Countries European Countries Scientific American Worldview Scorecard, 2016: Innovationpotential in biotechnology around the world

  6. For the International Competitiveness Strong IP Environment at International Standards is Needed Current Manufacturing Composition in Turkey Units (Million) Local Manufacturing %74 Import %26 Current Production in Turkey Higher value added phases where IP protected must be focused for international competitiveness Value (Billion) Local Manufacturing %47 Import %53

  7. To Improve Global Competititveness Turkey Should Integrate with Global Value Chain • A technological leap is essential to increase the share of high-tech and high value added export for the sustainable growth • Pharma and biotechnology are proritized in this technological transformation • Integration with global value chain is needed for global competitiveness • Competitive IP standards is one of the key elements to make the ecosystem attractive for biotech investments.

More Related